Trial Profile

A Multicenter Open-label Study Of Etanercept Withdrawal And Retreatment In Subjects With Non-radiographic Axial Spondyloarthritis Who Achieved Adequate 24 Week Response

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary) ; Nonsteroidal anti-inflammatories
Indications Non-radiographic axial spondyloarthritis
Focus Therapeutic Use
Acronyms RE-EMBARK
Sponsors Pfizer

Most Recent Events

15 Nov 2022 Results published in The Journal of Rheumatology
06 Jun 2020 Results assessing presented at the 21st Annual Congress of the European League Against Rheumatism.
01 Oct 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com